Advertisement

Etiologies of Blepharoptosis

  • Alexander Grigalunas
  • Aimee J. SzewkaEmail author
Chapter

Abstract

Blepharoptosis is a common presenting complaint of patients presenting for medical evaluation. As etiologies vary from acute neurologic issues to mechanical age-related changes, proper diagnosis is essential. Blepharoptosis may be a sign of impending neurologic or systemic disease, further warranting diagnostic evaluations. Proper treatment relies on accurate diagnosis of the underlying cause of blepharoptosis. This chapter discusses some of the most frequently seen causes of blepharoptosis both in adults and children, in particular focusing on the more concerning, “not to be missed” etiologies such as acute third nerve palsy, Horner’s syndrome, and myasthenia gravis. Typical presentations and diagnostic evaluations are discussed. Less frequent myopathic and neurologic causes of blepharoptosis as well as congenital blepharoptosis are included as well.

Keywords

Blepharoptosis Ptosis Congenital ptosis Acquired ptosis Pseudoptosis 

References

  1. 1.
    Rush JA, Younge BR. Paralysis of cranial nerves III, IV, and VI. Cause and prognosis in 1,000 cases. Arch Ophthalmol. 1981;99(1):76–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Keane JR, Ahmadi J. Most diabetic third nerve palsies are peripheral. Neurology. 1998;51(5):1510.PubMedCrossRefGoogle Scholar
  3. 3.
    Keane JR. Third nerve palsy: analysis of 1400 personally-examined inpatients. Can J Neurol Sci. 2010;37(5):662–70.PubMedCrossRefGoogle Scholar
  4. 4.
    Kung NH, Van Stavern GP. Isolated ocular motor nerve palsies. Semin Neurol. 2015;35(5):539–48.PubMedCrossRefGoogle Scholar
  5. 5.
    Elmalem VI, Hudgins PA, Bruce BB, Newman NJ, Biousse V. Underdiagnosis of posterior communicating artery aneurysm in noninvasive brain vascular studies. J Neuroophthalmol. 2011;31(2):103–9.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Maloney WF, Younge BR, Moyer NJ. Evaluation of the causes and accuracy of pharmacologic localization in Horner’s syndrome. Am J Ophthalmol. 1980;90(3):394–402.PubMedCrossRefGoogle Scholar
  7. 7.
    Koc F, Kavuncu S, Kansu T, Acaroglu G, Firat E. The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis. Br J Ophthalmol. 2005;89(11):1442–4.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Glatt HJ, Putterman AM, Fett DR. Muller’s muscle-conjunctival resection procedure in the treatment of ptosis in Horner’s syndrome. Ophthalmic Surg. 1990;21(2):93–6.PubMedGoogle Scholar
  9. 9.
    Pang NK, Newsom RW, Oestreicher JH, Chung HT, Harvey JT. Fasanella-Servat procedure: indications, efficacy, and complications. Can J Ophthalmol. 2008;43(1):84–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Baylis HI, Shorr N. Anterior tarsectomy reoperation for upper eyelid blepharoptosis or contour abnormalities. Am J Ophthalmol. 1977;84(1):67–71.PubMedCrossRefGoogle Scholar
  11. 11.
    Zadikoff C, Lang AE. Apraxia in movement disorders. Brain. 2005;128(Pt 7):1480–97.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee KC, Finley R, Miller B. Apraxia of lid opening: dose-dependent response to carbidopa-levodopa. Pharmacotherapy. 2004;24(3):401–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Kanazawa M, Shimohata T, Sato M, Onodera O, Tanaka K, Nishizawa M. Botulinum toxin a injections improve apraxia of eyelid opening without overt blepharospasm associated with neurodegenerative diseases. Mov Disord. 2007;22(4):597–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci. 1987;505:472–99.PubMedCrossRefGoogle Scholar
  15. 15.
    Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475–90.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Sethi KD, Rivner MH, Swift TR. Ice pack test for myasthenia gravis. Neurology. 1987;37(8):1383–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Fakiri MO, Tavy DL, Hama-Amin AD, Wirtz PW. Accuracy of the ice test in the diagnosis of myasthenia gravis in patients with ptosis. Muscle Nerve. 2013;48(6):902–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Cromar A, Lozier BK, Haven TR, Hill HR. Detection of acetylcholine receptor blocking antibodies by flow cytometry. Am J Clin Pathol. 2016;145(1):81–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36–40.PubMedCrossRefGoogle Scholar
  20. 20.
    Gwathmey KG, Burns TM. Myasthenia gravis. Semin Neurol. 2015;35(4):327–39.PubMedCrossRefGoogle Scholar
  21. 21.
    Mao ZF, Mo XA, Qin C, Lai YR, Hackett ML. Incidence of thymoma in myasthenia gravis: a systematic review. J Clin Neurol. 2012;8(3):161–9.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Mao ZF, Yang LX, Mo XA, Qin C, Lai YR, He NY, et al. Frequency of autoimmune diseases in myasthenia gravis: a systematic review. Int J Neurosci. 2011;121(3):121–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256(8):1314–20.PubMedCrossRefGoogle Scholar
  24. 24.
    Suominen T, Bachinski LL, Auvinen S, Hackman P, Baggerly KA, Angelini C, et al. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet. 2011;19(7):776–82.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Romeo V. Myotonic dystrophy type 1 or Steinert’s disease. Adv Exp Med Biol. 2012;724:239–57.PubMedCrossRefGoogle Scholar
  26. 26.
    Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology. 2003;60(4):657–64.PubMedCrossRefGoogle Scholar
  27. 27.
    Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol. 1997;37(4):212–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Rajabi MT, Tabatabaie SZ, Rajabi MB, Abrishami Y, Hosseini SS, Oestreicher J. Management of myogenic ptosis in chronic progressive external ophthalmoplegia. Iran J Neurol. 2014;13(3):185–7.PubMedPubMedCentralGoogle Scholar
  29. 29.
    De Braekeleer M. Hereditary disorders in Saguenay-Lac-St-Jean (Quebec, Canada). Hum Hered. 1991;41(3):141–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Blumen SC, Nisipeanu P, Sadeh M, Asherov A, Blumen N, Wirguin Y, et al. Epidemiology and inheritance of oculopharyngeal muscular dystrophy in Israel. Neuromuscul Disord. 1997;7(Suppl 1):S38–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Harish P, Malerba A, Dickson G, Bachtarzi H. Progress on gene therapy, cell therapy, and pharmacological strategies toward the treatment of oculopharyngeal muscular dystrophy. Hum Gene Ther. 2015;26(5):286–92.PubMedCrossRefGoogle Scholar
  32. 32.
    Hosal BM, Tekeli O, Gursel E. Eyelid malpositions after cataract surgery. Eur J Ophthalmol. 1998;8(1):12–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Altieri M, Truscott E, Kingston AE, Bertagno R, Altieri G. Ptosis secondary to anterior segment surgery and its repair in a two-year follow-up study. Ophthalmologica. 2005;219(3):129–35.PubMedCrossRefGoogle Scholar
  34. 34.
    Loeffler M, Solomon LD, Renaud M. Postcataract extraction ptosis: effect of the bridle suture. J Cataract Refract Surg. 1990;16(4):501–4.PubMedCrossRefGoogle Scholar
  35. 35.
    Kitazawa T. Hard contact lens wear and the risk of acquired blepharoptosis: a case-control study. Eplasty. 2013;19(13):e30.Google Scholar
  36. 36.
    Bleyen I, Hiemstra CA, Devogelaere T, van den Bosch WA, Wubbels RJ, Paridaens DA. Not only hard contact lens wear but also soft contact lens wear may be associated with blepharoptosis. Can J Ophthalmol. 2011;46(4):333–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Mun KS, Pailoor J, Reddy SC. Primary localised deep cutaneous amyloidosis of the eyelid. Malays J Pathol. 2005;27(2):113–5.PubMedGoogle Scholar
  38. 38.
    Yang CC, Vagefi MR, Davis D, Mamalis N, Anderson RL, McCann J. Gouty tophus of the upper eyelid. Ophthal Plast Reconstr Surg. 2008;24(5):404–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Scuderi G, Mutolo MG, Lambiase A, Recupero SM. Surgical management of concomitant ptosis and cicatricial entropion in a patient with ocular cicatricial pemphigoid. Int J Ophthalmol Clin Res. 2015;2(3):32.Google Scholar
  40. 40.
    Koursh DM, Modjtahedi SP, Selva D, Leibovitch I. The blepharochalasis syndrome. Surv Ophthalmol. 2009;54(2):235–44.PubMedCrossRefGoogle Scholar
  41. 41.
    Langley KE, Patrinely JR, Anderson RL, Thiese SM. Unilateral blepharochalasis. Ophthalmic Surg. 1987;18(8):594–8.PubMedGoogle Scholar
  42. 42.
    Sarnat HB, Flores-Sarnat L, Kherani F. Palpebral myopathology of congenital ptosis. Presented at the 57th annual meeting of the German Society for Neuropathology and Neuroanatomy. Erlangen, Germany; 2012.Google Scholar
  43. 43.
    Crawford JS. Repair of ptosis using frontalis muscle and fascia lata: a 20-year review. Ophthalmic Surg. 1977;8(4):31–40.PubMedGoogle Scholar
  44. 44.
    Hamed LM. Associated neurologic and ophthalmologic findings in congenital oculomotor nerve palsy. Ophthalmology. 1991;98(5):708–14.PubMedCrossRefGoogle Scholar
  45. 45.
    Langmann A, Lindner S. Congenital third nerve palsy in septo-optic dysplasia. Br J Ophthalmol. 2004;88(7):969.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Smith SJ, Diehl N, Leavitt JA, Mohney BG. Incidence of pediatric Horner syndrome and the risk of neuroblastoma: a population-based study. Arch Ophthalmol. 2010;128(3):324–9.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Yamada K, Hunter DG, Andrews C, Engle EC. A novel KIF21A mutation in a patient with congenital fibrosis of the extraocular muscles and Marcus Gunn jaw-winking phenomenon. Arch Ophthalmol. 2005;123(9):1254–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Kirkham TH. Familial Marcus Gunn phenomenon. Br J Ophthalmol. 1969;53(4):282–3.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Demirci H, Frueh BR, Nelson CC. Marcus Gunn jaw-winking synkinesis: clinical features and management. Ophthalmology. 2010;117(7):1447–52.PubMedCrossRefGoogle Scholar
  50. 50.
    Bowyer JD, Sullivan TJ. Management of Marcus Gunn jaw winking synkinesis. Ophthal Plast Reconstr Surg. 2004;20(2):92–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Ibrahim HA. Use of the levator muscle as a frontalis sling. Ophthal Plast Reconstr Surg. 2007;23(5):376–80.PubMedCrossRefGoogle Scholar
  52. 52.
    Fukushima Y, Wakui K, Nishida T, Ueoka Y. Blepharophimosis sequence and de novo balanced autosomal translocation [46,XY,t(3;4)(q23;p15.2)]: possible assignment of the trait to 3q23. Am J Med Genet. 1991;40(4):485–7.PubMedCrossRefGoogle Scholar
  53. 53.
    De Baere E, Dixon MJ, Small KW, Jabs EW, Leroy BP, Devriendt K, et al. Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (BPES) families demonstrates a genotype – phenotype correlation. Hum Mol Genet. 2001;10(15):1591–600.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Departments of Ophthalmology and NeurologyRush University Medical CenterChicagoUSA

Personalised recommendations